CLDF Title
Home | Contact Us | Bookmark
About CLDF Centers of Educational Expertise  
Live CME Meetings Webcasts Slide Library Abstract Library Conference Highlights
Reuters Health Information (2011-04-27): Telbivudine during pregnancy safely reduces vertical transmission of HBV

Drug & Device Development

Telbivudine during pregnancy safely reduces vertical transmission of HBV

Last Updated: 2011-04-27 10:54:26 -0400 (Reuters Health)

NEW YORK (Reuters Health) - Perinatal transmission of hepatitis B virus (HBV) from highly viremic mothers to their offspring is substantially reduced with telbivudine therapy during pregnancy, without any apparent adverse effects, a team in China has shown.

Dr. Guo-Rong Han and colleagues, at the Second Affiliated Hospital of the Southeast University in Nanjing, explain in the Journal of Hepatology online April 18 that perinatal HBV infection is the main cause of chronic hepatitis B in the Asia-Pacific region.

Passive and active immunization given within 12 hours of birth can usually prevent transmission, but the strategy fails in up to 15% of cases when maternal HBV DNA levels are high.

To assess the utility and safety of telbivudine in this setting, the researchers enrolled 229 mothers with HBV DNA levels greater than 10 million copies/mL in an open-label trial. From gestational week 20 to week 32, telbivudine 600 mg/d was given to 135 of the women while 94 served as controls.

All the infants were given HBIg within 12 hours postpartum, and received HBV vaccine at 0, 1 and 6 months.

"Seven months after delivery, the incidence of perinatal transmission was lower in the infants that completed follow-up born to the telbivudine-treated mothers than to the controls (0% vs. 8%; p=0.002)," Dr. Han and colleagues report.

Furthermore, the incidence and nature of adverse events were similar in the two groups, and none were considered to be drug related.

Based on the results, the authors conclude that telbivudine "should be recommended in pregnant women who are at high risk of transmitting HBV infection to their newborns."

However, they add, "Additional randomized, multi-center, long-term follow-up studies are needed to better define the utility of telbivudine in preventing transmission. The best timing for intervention with telbivudine should be further studied."


J Hepatol 2011.

Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Sponsors & Supporters
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
Centers of
Educational Expertise
Substance Use Disorder
CLDF Follow Us
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2018 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.